\-\ Texto\\:\\ \ \(0\)\
\-\ \\â\\€\\¢\\ positive\\ csf\\ for\\ tau\ \(0\)\
\-\ \\â\\€\\¢\\ positive\\ csf\\ for\\ 14\\-3\\-3\\ protein\ \(0\)\
\-\ \\â\\€\\¢\\ abnormal\\ eeg\\ with\\ sharply\\ contoured\\ slow\\ wave\\ activity\\ left\\ frontal\\ and\\ temporal\\ region\\.\ \(0\)\
\-\ supportive\ \(54\)\
\-\ abnormal\\ signal\\ involving\\ head\\ of\\ caudate\\,\\ putamen\\,\\ and\\ left\\ partietal\\ cortex\\ on\\ flair\\,\\ t2\\,\\ dwi\\ and\\ adc\\ map\\.\ \(0\)\
\-\ no\\ pathologic\\ enhancement\\ or\\ mass\\ effect\\.\ \(0\)\
\-\ spongiform\\ encephalopathy\\;\\ \\ presumed\\ variant\\ creutzfeldt\\-jacob\\ disease\ \(0\)\
\-\ post\\-ictal\\ state\\.\ \(2\)\
\-\ encephalitis\ \(55\)\
\-\ infarction\ \(233\)\
\-\ 68\\ year\\ old\\ woman\\ admitted\\ to\\ neurology\\ service\\ with\\ altered\\ mental\\ status\\ and\\ \\ new\\ onset\\ seizures\\.\ \(1\)\
\-\ positive\\ csf\\ for\\ tau\\;\\ and\\,\\ positive\\ csf\\ for\\ 14\\-3\\-3\\ protein\\ \\-\\ \\ suggested\\ to\\ be\\ 85\\%\\ specific\\ for\\ cjd\\.\ \(0\)\
\-\ source\\ \\-\\ pmid\\:\\ 12933920\ \(0\)\
\-\ http\\:\\/\\/www\\.ncbi\\.nlm\\.nih\\.gov\\/pmc\\/articles\\/pmc1738637\\/\ \(0\)\
\-\ \\"both\\ 14\\-3\\-3\\ and\\ tau\\ protein\\ are\\ sensitive\\ and\\ specific\\ biomarkers\\ for\\ cjd\\.\\ the\\ combination\\ of\\ 14\\-3\\-3\\ and\\ b\\ amyloid\\ analysis\\ resulted\\ in\\ the\\ maximum\\ sensitivity\\,\\ specificity\\,\\ and\\ positive\\ predictive\\ value\\.\\ when\\ these\\ biomarkers\\ are\\ used\\ in\\ the\\ diagnosis\\ of\\ cjd\\,\\ the\\ phase\\ of\\ the\\ disease\\ in\\ which\\ the\\ csf\\ sample\\ was\\ obtained\\ should\\ be\\ taken\\ into\\ account\\.\\ disease\\ duration\\,\\ dependent\\ on\\ the\\ prp\\ genotype\\,\\ also\\ has\\ a\\ significant\\ influence\\ on\\ the\\ level\\ of\\ 14\\-3\\-3\\ and\\ tau\\ in\\ the\\ csf\\.\\"\ \(0\)\
\-\ http\\:\\/\\/www\\.ncbi\\.nlm\\.nih\\.gov\\/pmc\\/articles\\/pmc1738637\\/pdf\\/v074p01210\\.pdf\\ \ \(0\)\
\-\ pmid\\:\\ 16023527\ \(0\)\
\-\ pmid\\:\\ 19418113\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ tau\\:\\ 0\\.3509937059201179\ \(0\)\
\-\ csf\\:\\ 0\\.2815278475285191\ \(0\)\
\-\ cjd\\:\\ 0\\.2562766128195251\ \(0\)\
\-\ positive\\:\\ 0\\.19564686070434117\ \(0\)\
\-\ pmid\\:\\ 0\\.19550676747793663\ \(0\)\
\-\ biomarkers\\:\\ 0\\.18148630218477596\ \(0\)\
\-\ protein\\:\\ 0\\.16532529137488247\ \(0\)\
\-\ and\\:\\ 0\\.12270464166743712\ \(0\)\
\-\ for\\:\\ 0\\.1079884984305464\ \(0\)\
\-\ the\\:\\ 0\\.10663888474409974\ \(0\)\
\-\ partietal\\:\\ 0\\.0949639783700684\ \(0\)\
\-\ 12933920\\:\\ 0\\.0949639783700684\ \(0\)\
\-\ prp\\:\\ 0\\.0949639783700684\ \(0\)\
\-\ 16023527\\:\\ 0\\.0949639783700684\ \(0\)\
\-\ 19418113\\:\\ 0\\.0949639783700684\ \(0\)\
\-\ genotype\\:\\ 0\\.09074315109238798\ \(0\)\
\-\ specific\\:\\ 0\\.08999526884302114\ \(0\)\
\-\ http\\:\\ 0\\.08780169642662275\ \(0\)\
\-\ spongiform\\:\\ 0\\.08774842648002948\ \(0\)\
\-\ influence\\:\\ 0\\.08192291514624452\ \(0\)\
\-\ contoured\\:\\ 0\\.08053287458999057\ \(0\)\
\-\ predictive\\:\\ 0\\.07547881545789928\ \(0\)\
\-\ sample\\:\\ 0\\.07547881545789928\ \(0\)\
\-\ disease\\:\\ 0\\.07477875804387522\ \(0\)\
\-\ putamen\\:\\ 0\\.073989158438789\ \(0\)\
\-\ abnormal\\:\\ 0\\.07135124452599559\ \(0\)\
\-\ eeg\\:\\ 0\\.07099443382643052\ \(0\)\
\-\ caudate\\:\\ 0\\.069539534238372\ \(0\)\
\-\ wave\\:\\ 0\\.06909649542227121\ \(0\)\
\-\ specificity\\:\\ 0\\.06787039275694927\ \(0\)\
\-\ map\\:\\ 0\\.06749181136616668\ \(0\)\
\-\ sharply\\:\\ 0\\.06712651630894141\ \(0\)\
\-\ amyloid\\:\\ 0\\.06712651630894141\ \(0\)\
\-\ maximum\\:\\ 0\\.06302603535346503\ \(0\)\
\-\ neurology\\:\\ 0\\.06278671812571074\ \(0\)\
\-\ encephalopathy\\:\\ 0\\.06255277927106964\ \(0\)\
\-\ service\\:\\ 0\\.06145599306287045\ \(0\)\
\-\ adc\\:\\ 0\\.061249850862740235\ \(0\)\
\-\ presumed\\:\\ 0\\.06065484086691035\ \(0\)\
\-\ resulted\\:\\ 0\\.0604638292521896\ \(0\)\
\-\ value\\:\\ 0\\.0604638292521896\ \(0\)\
\-\ account\\:\\ 0\\.0604638292521896\ \(0\)\
\-\ altered\\:\\ 0\\.060276259476127754\ \(0\)\
\-\ sensitivity\\:\\ 0\\.060276259476127754\ \(0\)\
\-\ state\\:\\ 0\\.05991096441890249\ \(0\)\
\-\ in\\:\\ 0\\.05908878031370774\ \(0\)\
\-\ encephalitis\\:\\ 0\\.059050156810805804\ \(0\)\
\-\ sensitive\\:\\ 0\\.05840934893675508\ \(0\)\
\-\ of\\:\\ 0\\.0581035034476036\ \(0\)\
\-\ slow\\:\\ 0\\.05723516578519002\ \(0\)\
\-\ duration\\:\\ 0\\.05723516578519002\ \(0\)\
\-\ dependent\\:\\ 0\\.05723516578519002\ \(0\)\
\-\ 68\\:\\ 0\\.05709728508165329\ \(0\)\
\-\ source\\:\\ 0\\.05656333004635267\ \(0\)\
\-\ dwi\\:\\ 0\\.05643401358922992\ \(0\)\
\-\ suggested\\:\\ 0\\.055571166235671814\ \(0\)\
\-\ analysis\\:\\ 0\\.055222200344036465\ \(0\)\
\-\ combination\\:\\ 0\\.05510843045829415\ \(0\)\
\-\ 85\\:\\ 0\\.05477439620813215\ \(0\)\
\-\ on\\:\\ 0\\.05380271520313828\ \(0\)\
\-\ variant\\:\\ 0\\.052695412528863575\ \(0\)\
\-\ mental\\:\\ 0\\.05175231325958236\ \(0\)\
\-\ phase\\:\\ 0\\.05081244154774152\ \(0\)\
\-\ flair\\:\\ 0\\.050517107103580525\ \(0\)\
\-\ supportive\\:\\ 0\\.04961133251010209\ \(0\)\
\-\ pathologic\\:\\ 0\\.048655630526292425\ \(0\)\
\-\ admitted\\:\\ 0\\.048655630526292425\ \(0\)\
\-\ seizures\\:\\ 0\\.04847458525118314\ \(0\)\
\-\ cortex\\:\\ 0\\.04835561434563289\ \(0\)\
\-\ be\\:\\ 0\\.048177417691529494\ \(0\)\
\-\ taken\\:\\ 0\\.047449839752154443\ \(0\)\
\-\ infarction\\:\\ 0\\.04661660789774359\ \(0\)\
\-\ temporal\\:\\ 0\\.045615348550504156\ \(0\)\
\-\ are\\:\\ 0\\.045065172604206394\ \(0\)\
\-\ used\\:\\ 0\\.04445511513979597\ \(0\)\
\-\ activity\\:\\ 0\\.0435968896577026\ \(0\)\
\-\ obtained\\:\\ 0\\.04200290980915208\ \(0\)\
\-\ effect\\:\\ 0\\.0416553562831561\ \(0\)\
\-\ involving\\:\\ 0\\.04159339276134073\ \(0\)\
\-\ status\\:\\ 0\\.041440078636253506\ \(0\)\
\-\ new\\:\\ 0\\.0410810830291019\ \(0\)\
\-\ left\\:\\ 0\\.040512663377758544\ \(0\)\
\-\ should\\:\\ 0\\.038746438263954144\ \(0\)\
\-\ frontal\\:\\ 0\\.03821953517039032\ \(0\)\
\-\ onset\\:\\ 0\\.03813056162935774\ \(0\)\
\-\ when\\:\\ 0\\.03586987429515453\ \(0\)\
\-\ level\\:\\ 0\\.03586987429515453\ \(0\)\
\-\ region\\:\\ 0\\.03551934148232573\ \(0\)\
\-\ head\\:\\ 0\\.03541644271109315\ \(0\)\
\-\ significant\\:\\ 0\\.03428558170674384\ \(0\)\
\-\ enhancement\\:\\ 0\\.03417896938278481\ \(0\)\
\-\ t2\\:\\ 0\\.03416382779330934\ \(0\)\
\-\ signal\\:\\ 0\\.03366169557331602\ \(0\)\
\-\ these\\:\\ 0\\.03353273512381728\ \(0\)\
\-\ both\\:\\ 0\\.03311405238229029\ \(0\)\
\-\ into\\:\\ 0\\.031566193951897956\ \(0\)\
\-\ woman\\:\\ 0\\.030926089932945048\ \(0\)\
\-\ diagnosis\\:\\ 0\\.03078295924648001\ \(0\)\
\-\ to\\:\\ 0\\.029690526868609977\ \(0\)\
\-\ also\\:\\ 0\\.027931365320586557\ \(0\)\
\-\ has\\:\\ 0\\.027123748245165398\ \(0\)\
\-\ which\\:\\ 0\\.027001368103240154\ \(0\)\
\-\ with\\:\\ 0\\.023255288110827298\ \(0\)\
\-\ mass\\:\\ 0\\.02268215555517016\ \(0\)\
\-\ was\\:\\ 0\\.020695047732600273\ \(0\)\
\-\ or\\:\\ 0\\.020657773545824397\ \(0\)\
\-\ no\\:\\ 0\\.019310194718651835\ \(0\)\
\-\ year\\:\\ 0\\.018300215437259137\ \(0\)\
\-\ old\\:\\ 0\\.017574541596549843\ \(0\)\
